ArticleJournal of medicinal chemistry2021
A Novel Triphenylphosphonium Carrier to Target Mitochondria without Uncoupling Oxidative Phosphorylation.
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Synthesis and biological evaluation of tris(4-methoxyphenyl)phosphonium-hydrazone derivatives against clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates: antibacterial, antibiofilm, and gene expression analyses.Folia microbiologica · 2026Article
- Organelle-Resolved Tetrazine-trans-Cyclooctene Click Chemistry for Cargo Delivery and Release.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- N8-Modified Quino[4,3,2-Kl]acridines as Promising Antimalarial G-Quadruplex Ligands.Chembiochem : a European journal of chemical biology · 2026Article
- Natural Small Molecules Targeting Mitochondrial Quality Control for the Treatment of Metabolic Diseases: Mechanisms, Novel Formulations, and Translational Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Redox and structural determinants of mitochondrial complex III inhibition by triphenylphosphonium-conjugated atovaquone analogs.Redox biology · 2026Article
- Targeting SIRT3 in Diabetic Cardiomyopathy: Mechanism-Based Therapeutic Strategies.Cardiovascular drugs and therapy · 2026Review
- Mitochondria-Targeting Moieties Based on N-Tethered Pyridinium Cations.Angewandte Chemie (International ed. in English) · 2026Article
- Mitochondria-Targeting Metal Complexes: Design Principles, Mechanisms of Action, and Translational Perspectives.Biomolecules · 2026Review
- Triphenylphosphonium compounds preferentially inhibit long-chain fatty acid oxidation in cardiac mitochondria.Research square · 2026Article
- Non-Cytotoxic Benzyl Triphenyl Phosphonium Bromide Is Bactericidal on MRSA and Fully Inhibits Biofilm Formation by MRSA and MRSE.Pharmaceuticals (Basel, Switzerland) · 2026Article
- In Vitro Doxorubicin Delivery Using TPP-Folate-Dendrimer-Functionalized Gold Nanoclusters.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Kinetoplast-Directed Therapies: A Selective Mitochondrial Approach to Combat Leishmaniasis.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Alkyltriphenylphosphonium Binding to Cardiolipin Triggers Oncosis in Cancer Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Development of Mitochondria-Targeted PARP Inhibitors.Biomolecules · 2026Article
- Modular Design of Mitochondrion-Targeted Iron Chelators Allows Highly Selective Antiparasitic Activity against Trypanosomes and Apicomplexan Parasites.ACS infectious diseases · 2026Article
- Targeting mitochondria for the treatment of neurodegenerative diseases.Frontiers in neuroscience · 2026Review
- Mitochondria in health and disease: cellular powerhouses, signaling centers, and drivers of dysfunction.Frontiers in cell and developmental biology · 2026Review
- Nanomedicines Against Mitochondrial Dysfunction-Induced Metabolic Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Lipophilic Cations as Mitochondria-Targeting Moieties: Recent Progress and Design Principles for Medicinal Chemistry.Journal of medicinal chemistry · 2025Review
- Programmed Cell Death via Type IV Photodynamic Therapy Using Internalized Two-Photon Activated Molecular Nanomachines.ACS applied bio materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Chaitanya A KulkarniDivision of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, Iowa 52242, United States.ORCID 0000-0002-6836-0518
Brian D FinkDivision of Endocrinology and Metabolism, Department of Internal Medicine, University of Iowa and the Iowa City Veterans Affairs Medical Center, Iowa City, Iowa 52246, United States.
Bettine E GibbsDivision of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, Iowa 52242, United States.ORCID 0000-0001-5083-5143
Pratik R ChhedaDivision of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, Iowa 52242, United States.
Meng WuDivision of Endocrinology and Metabolism, Department of Internal Medicine, University of Iowa and the Iowa City Veterans Affairs Medical Center, Iowa City, Iowa 52246, United States.ORCID 0000-0003-2222-0736
William I SivitzDivision of Endocrinology and Metabolism, Department of Internal Medicine, University of Iowa and the Iowa City Veterans Affairs Medical Center, Iowa City, Iowa 52246, United States.
Robert J KernsDivision of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Therapeutics, University of Iowa, Iowa City, Iowa 52242, United States.ORCID 0000-0001-5371-403X
Funding
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0MPREDOCTORAL TRAINING PROGRAM IN BIOTECHNOLOGYT32GM008365 · NIGMS · UNIVERSITY OF IOWA · PI KERNS, ROBERT JOHN · 1990 to 2021
$3.8MUCP1 and the regulation of mitochondrial respiration in brown adipose tissue by oxaloacetateR01DK123043 · NIDDK · UNIVERSITY OF IOWA · PI SIVITZ, WILLIAM IRVING · 2020 to 2023
$1.3MCore-based Scientist specializing in high throughput screening for early drug discovery, target identification and systems biology analysis of cancerR50CA243786 · NCI · UNIVERSITY OF IOWA · PI WU, MENG · 2019 to 2023
$935kHigh Throughput Drug Screening RobotS10RR029274 · NCRR · UNIVERSITY OF IOWA · PI RICE, KEVIN G · 2011 to 2011
$730kMitochondrial-targeted CoQ: Metabolic and Redox Effects and role in DiabetesI01BX000285 · VA · IOWA CITY VA MEDICAL CENTER · PI SIVITZ, WILLIAM IRVING · 2011 to 2017
–BLRD VA I01 BX000285NCI NIH HHS P30 CA086862NCI NIH HHS R50 CA243786NCRR NIH HHS S10 RR029274NIDDK NIH HHS R01 DK123043NIGMS NIH HHS T32 GM008365
Abstract
Mitochondrial dysfunction is an underlying pathology in numerous diseases. Delivery of diagnostic and therapeutic cargo directly into mitochondria is a powerful approach to study and treat these diseases. The triphenylphosphonium (TPP
Indexed as
Drug CarriersCell SurvivalChromatography, High Pressure LiquidHumansMitochondriaOrganophosphorus CompoundsOxidative PhosphorylationDrug CarriersOrganophosphorus Compounds
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.